Sangamo Therapeutics, Inc. (SGMOQ)
0.1475
0.00 (0.00%)
USD |
OTCM |
Oct 02, 16:00
Sangamo Therapeutics Max Drawdown (5Y) : 99.68% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 99.68% |
| August 31, 2026 | 99.68% |
| July 31, 2026 | 99.68% |
| June 30, 2026 | 99.68% |
| May 31, 2026 | 99.17% |
| April 30, 2026 | 99.02% |
| March 31, 2026 | 98.37% |
| February 28, 2026 | 98.37% |
| January 31, 2026 | 98.37% |
| December 31, 2025 | 98.37% |
| November 30, 2025 | 98.37% |
| October 31, 2025 | 98.37% |
| September 30, 2025 | 98.37% |
| August 31, 2025 | 98.37% |
| July 31, 2025 | 98.37% |
| June 30, 2025 | 98.37% |
| May 31, 2025 | 98.37% |
| April 30, 2025 | 98.37% |
| March 31, 2025 | 98.37% |
| February 28, 2025 | 98.37% |
| January 31, 2025 | 98.37% |
| December 31, 2024 | 98.37% |
| November 30, 2024 | 98.37% |
| October 31, 2024 | 98.37% |
| September 30, 2024 | 98.37% |
| Date | Value |
|---|---|
| August 31, 2024 | 98.37% |
| July 31, 2024 | 98.37% |
| June 30, 2024 | 98.37% |
| May 31, 2024 | 98.37% |
| April 30, 2024 | 98.37% |
| March 31, 2024 | 98.37% |
| February 29, 2024 | 98.37% |
| January 31, 2024 | 98.37% |
| December 31, 2023 | 98.37% |
| November 30, 2023 | 98.37% |
| October 31, 2023 | 97.44% |
| September 30, 2023 | 96.82% |
| August 31, 2023 | 95.96% |
| July 31, 2023 | 94.17% |
| June 30, 2023 | 94.17% |
| May 31, 2023 | 94.12% |
| April 30, 2023 | 93.03% |
| March 31, 2023 | 92.64% |
| February 28, 2023 | 89.92% |
| January 31, 2023 | 89.49% |
| December 31, 2022 | 89.49% |
| November 30, 2022 | 87.55% |
| October 31, 2022 | 87.55% |
| September 30, 2022 | 87.55% |
| August 31, 2022 | 87.55% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 88.96% |
| Oncolytics Biotech, Inc. | 92.83% |
| Sarepta Therapeutics, Inc. | 93.33% |
| Anixa Biosciences, Inc. | 70.17% |
| Vicapsys Life Sciences, Inc. | 100.0% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -75.49 |
| Beta (5Y) | 1.561 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 146.7% |
| Historical Sharpe Ratio (5Y) | -0.4081 |
| Historical Sortino (5Y) | -1.133 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 44.76% |